Le marché des aspergillos systémiques et de la candidose systémique devrait atteindre 8 247,5 millions de dollars US d'ici 2027 contre 6 056,3 millions de dollars US en 2019. Le marché devrait croître à un TCAC de 4,0 % de 2020 à 2027.
Candida Auris est un champignon qui représente une grave menace pour la santé mondiale. Il provoque une maladie grave chez les patients hospitalisés dans plusieurs pays, dont les États-Unis. Les patients peuvent rester longtemps colonisés par C. Auris. En outre, C. Auris peut persister sur les surfaces dans les environnements de soins de santé. Cela peut entraîner la propagation de C. Auris entre les patients dans les établissements de santé. Selon un rapport du CDC de 2021, des cas américains de C. Auris ont été découverts chez des patients ayant récemment séjourné dans des établissements de santé en Égypte, en Inde, au Kenya, au Koweït, au Pakistan, en Afrique du Sud, en Corée du Sud, aux Émirats arabes unis et au Venezuela, ce qui ont également des cas documentés. Ainsi, cela peut être une infection nosocomiale. L'émergence de Candida Auris est considérée comme l'un des problèmes les plus graves associés à la transmission nosocomiale et aux pratiques de contrôle des infections en milieu hospitalier. De plus, le CDC a déclaré que 560 cas d'infections à C. Auris avaient été signalés aux États-Unis au 31 janvier 2019. De plus, malgré l'exécution de contre-mesures pour limiter les infections fongiques dans les unités de soins intensifs (USI), des cas continuent d'être observés et signalés. , avec une tendance à un schéma endémique. Cela montre la capacité de C. Auris à une infection persistante dans l'environnement clinique, permettant sa transmission dans le cadre des soins intensifs. Contrairement aux autres espèces de Candida, C. Auris peut coloniser différents sites anatomiques (p. ex., peau, aisselle, rectum et selles) et contaminer l'équipement et les surfaces de l'hôpital, créant un cercle vicieux de propagation, d'acquisition et d'infection, en particulier dans les unités de soins intensifs.< /p>
De plus, selon un rapport du NCBI publié en janvier 2020, l'augmentation du nombre de voyages dans des pays étrangers et l'exposition aux soins de santé dans les pays où la transmission de C. Auris est importante ainsi que le flux plus élevé de migrants sont des facteurs qui peuvent contribuent à la dissémination rapide de cette espèce. En outre, une fréquence plus élevée de C. Auris a été trouvée dans les hôpitaux publics par rapport aux hôpitaux privés, ce qui peut être lié à la surpopulation et à des mesures de contrôle des infections compromises. De plus, 7 patients sur 1 000 admis dans les unités de soins intensifs à travers l'Inde sont touchés par une infection fongique, selon une analyse préliminaire des données recueillies par des chercheurs de l'Institut post-universitaire d'éducation et de recherche médicales de Chandigarh. Les données ont été recueillies auprès de 27 unités de soins intensifs d'hôpitaux à travers le pays (11 hôpitaux publics et 16 hôpitaux privés). Ainsi, l'incidence croissante des infections fongiques nosocomiales crée la demande de médicaments pouvant prévenir l'aspergillose systémique et la candidose systémique. Ceci, à son tour, devrait stimuler la croissance du marché de l'aspergillose systémique et de la candidose systémique.
Marchés régionaux lucratifs pour l'aspergillose systémique et la candidose systémique
Aperçu du marché
Augmentation de la prévalence des maladies fongiques
L'aspergillose systémique et la candidose systémique sont des types d'infections fongiques. L'infection par l'aspergillose est causée par des moisissures. Il affecte principalement les voies respiratoires d'un individu. Il s'agit d'une infection pulmonaire grave causée par Aspergillus, un champignon commun qui affecte les personnes dont le système immunitaire est affaibli ou qui souffrent de maladies pulmonaires. De plus, des infections fongiques graves surviennent en raison d'autres problèmes de santé, notamment l'asthme, le cancer, le sida, la transplantation d'organes et les corticothérapies. Un diagnostic précoce permet un traitement antifongique rapide ; cependant, cela est souvent retardé ou indisponible, entraînant une maladie chronique grave, la mort ou la cécité. Par exemple, selon le Journal of Fungi publié en mars 2017, la pandémie de VIH/sida, la tuberculose, la maladie pulmonaire obstructive chronique (MPOC), l'asthme et l'incidence croissante des cancers sont les principaux moteurs des infections fongiques dans les pays développés et en développement dans le monde. . En outre, un rapport publié par la National Library of Medicine National Institutes of Health en octobre 2017 a déclaré qu'environ 3 000 000 cas d'aspergillose pulmonaire chronique; ~223 100 cas de méningite cryptococcique compliquant le VIH/SIDA ; ~700 000 cas de candidose invasive ; ~500 000 cas de pneumonie à Pneumocystis jirovecii ; ~250 000 cas d'aspergillose invasive ; ~100 000 cas d'histoplasmose disséminée ; plus de 10 000 000 cas d'asthme fongique ; et environ 1 000 000 cas de kératite fongique surviennent chaque année dans le monde. De plus, selon un rapport des Centers for Disease Control and Prevention (CDC), environ 1 595 cas de Candida Auris ont été observés dans différents États des États-Unis.
Type Insights
En fonction du type, le marché de l'aspergillose systémique et de la candidose systémique est segmenté en voriconazole, amphotéricine b liposomale, azoles oraux systémiques, agents antifongiques topiques et autres. En 2019, le segment des azoles oraux systémiques détenait la plus grande part de marché. Le même segment devrait croître au rythme le plus rapide au cours de la période de prévision en raison du nombre croissant d'infections fongiques invasives.
Marché mondial de l'aspergillose systémique et de la candidose systémique, par produit - 2019 et 2027
< br />
Application Insights
Sur la base des applications, le marché mondial de l'aspergillose systémique et de la candidose systémique est segmenté en aspergillose pulmonaire chronique (APC), aspergillose bronchopulmonaire allergique (ABPA ), candidose gastro-intestinale, tractus génito-urinaire, candidose et autres. En 2019, le segment de l'aspergillose broncho-pulmonaire allergique (ABPA) détenait la plus grande part du marché. Le même segment devrait croître au rythme le plus rapide au cours de la période de prévision.
Perspectives stratégiques
Les lancements et les approbations de produits sont les stratégies couramment adoptées par les entreprises pour étendre leur empreinte mondiale et leurs produits portefeuilles pour répondre à la demande croissante des consommateurs. Les acteurs du marché de l'aspergillose systémique et de la candidose systémique adoptent la stratégie de collaborations pour élargir la clientèle dans le monde entier, ce qui leur permet également de conserver leur marque à l'échelle mondiale.
Marché de l'aspergillose systémique et de la candidose systémique - par type
- Azoles oraux systémiques
- Voriconazole
- Amphotéricine B liposomale
- Agents antifongiques topiques
- Autres < /ul>
- Aspergillose bronchopulmonaire allergique (ABPA)
- Aspergillose pulmonaire chronique (APC)
- Candidose gastro-intestinale
- Candidiose des voies génito-urinaires
- Autres
- Amérique du Nord
- États-Unis
- Canada
- Mexique
- Europe
- France
- Allemagne
- Italie
- Royaume-Uni
- Espagne
- Reste de l'Europe
- Asie-Pacifique (APAC)
- Chine
- Inde
- Corée du Sud
- Japon
- Australie
- Reste de l'Asie-Pacifique
- Moyen-Orient et Afrique (MEA)
- Afrique du Sud
- Arabie saoudite Arabie
- EAU
- Reste du Moyen-Orient et Afrique
- Amérique du Sud et centrale
- Brésil
- Argentine
- Reste de l'Amérique du Sud
- Novartis Ag
- Sanofi-Aventis
- Pfizer, Inc.
- Merck And Co., Inc.
- Enzon Pharmaceuticals Inc.
- Bayer Ag
- Astellas Pharma, Inc.
- Glaxosmithkline Plc
- Abbott
- Cipla
Marché de l'aspergillose systémique et de la candidose systémique - par application
Marché de l'aspergillose systémique et de la candidose systémique - par géographie
Profils des entreprises
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
The systemic aspergillosis and systemic candidiasis are the type of fungal infections. The aspergillosis infection is caused by molds and majorly affect the respiratory tract of an individual. The aspergillosis is not a severe condition but people with weakened immune system are prone to it. The candidiasis is caused by fungus called candida. The candidiasis is also known as thrush. The symptoms of candidiasis include patches in mouth and tongue. The treatment options for aspergillosis and candidiasis include drug therapy and surgery in some cases.
Driving factors for the market include rise in prevalence of fungal diseases and rising hospital acquired fungal infection. however, increasing resistance to antifungal drugs and side effects of antifungal drugs is likely to hamper the growth of the market during the forecast period.
Allergic bronchopulmonary aspergillosis (ABPA) have fastest growing segment among all segments.
The List of Companies - Systemic Aspergillosis and Systemic Candidiasis Market
- Novartis Ag
- Sanofi-Aventis
- Pfizer, Inc
- Merck And Co. Inc
- Enzon Pharmaceuticals, Inc
- Bayer Ag
- Astellas Pharma Inc
- Glaxosmithkline Plc
- Abbott
- Cipla
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.
Related Reports
Jan 2021
Aquatic Veterinary Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Type (Diagnostics and Treatments), Species (Fish, Crustaceans, Mollusca, and Others), Disease Source (Bacteria, Viruses, Parasites, and Others), Route of Administration (Water Medication, Medicated Feed, and Others), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jan 2021
Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis By Treatment (Generic Drugs and Originators), Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Jan 2021
Malaria and Sickle Cell Disease Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Treatment [Malaria and Sickle Cell Disease (SCD)], Route of Administration (Oral and Parenteral), and Distribution Channel (Direct Tender, Hospital Pharmacies, Retail Pharmacies, Online Pharmacies, and Others)
Jan 2021
Pharmaceutical Contract Sales Organizations Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Services (Commercial Services and Non-Commercial Services), Modules (Syndicated Modules and Dedicated Modules), Therapeutic Area (Cardiovascular Disorders, Oncology, Metabolic Disorders, Neurology, Orthopedic Diseases, Infectious Diseases, and Others), End User (Biopharmaceutical Companies and Pharmaceutical Companies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jan 2021
Breast Cancer Therapeutics Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Drug Therapy [Targeted Drug Therapy (Abemaciclib, Ado-Trastuzumab Emtansine, Palbociclib, Trastuzumab, and Other Target Drug Therapies), Hormonal Drug Therapy (Selective Estrogen Receptor Modulators, Aromatase Inhibitors, and Selective Estrogen Receptor Downregulators), Chemotherapy, and Immunotherapy/Biological Therapy], Breast Cancer Type (Hormone Receptor, HER2+, and Triple-Negative Breast Cancer), Distribution Channel (Hospital Pharmacies, Drug Stores and Retail Pharmacies, and Online Pharmacies), and Geography (North America, Europe, Asia Pacific, Middle East & Africa, and South & Central America)
Jan 2021
Radioactive Tracer Market
Size and Forecast to 2030 - Global Analysis by Tracer Type [Technetium-99m & Tc-97m, Iodine-131, Iron-59, Lutetium-171, Rubidium (Rb-82) Chloride & Ammonia (N-13), Scandium-46, Seaborgium-269, Hassium-269, Gallium Citrate Ga 67, Prostate-Specific Membrane Antigen (PSMA) (Ga-68), FDDNP (F-18) & FDOPA (F-18), Phosphorus-32 & Chromium-51, Thallium-201, F-18 FDG, F-18 FAPI, Ga-68 FAPI, F-18 PSMA, DOTATOC/DOTANOC/DOTATATE (Ga-68), and Others], Test Type (PET, SPECT, and Others), Application (Oncology, Pulmonary, Neurology, Cardiology, and Others) End User (Hospitals & Clinics, Diagnostic Centers, Academic & Research Institutes, And Others), and Geography
Jan 2021
Glioma Treatment Market
Size and Forecasts (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis Report Coverage: By Disease (Astrocytoma, Oligoastrocytoma, and Oligodendroglioma), Treatment Type (Surgery, Chemotherapy, Radiation Therapy, and Others), Grade (Low Grade and High Grade), End User (Hospital & Clinics and Ambulatory Surgical Center), and Geography
Jan 2021
Hyperpigmentation Disorder Treatment Market
Size and Forecast (2020 - 2030), Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Treatment Type (Cosmeceutical, Light or Laser Therapy, Microdermabrasion, Chemical Peels, Cryotherapy, and Others), Condition (Melasma, Solar Lentigines, Post-Inflammatory Hyperpigmentation, and Others), End User (Hospitals, Dermatology Centers, and Others), and Geography (North America, Europe, Asia Pacific, South & Central America, and Middle East & Africa)